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OBJECTIVE—The A1C-Derived Average Glucose (ADAG) study demonstrated a linear re-
lationship between HbA1c and mean plasma glucose (MPG). As glucose variability (GV) may
contributetoglycation,weexaminedtheassociationofseveralglucosevariabilityindicesandthe
MPG-HbA1c relationship.
RESEARCH DESIGN AND METHODS—Analyses included 268 patients with type 1
diabetes and 159 with type 2 diabetes. MPG during 3 months was calculated from 7-point self-
monitored plasma glucose and continuous glucose monitoring. We calculated three different
measures of GV and used a multiple-step regression model to determine the contribution of the
respective GV measures to the MPG-HbA1c relationship.
RESULTS—GV, as reﬂected by SD and continuous overlapping net glycemic action, had a
signiﬁcant effect on the MPG-HbA1c relationship in type 1 diabetic patients so that high GV led
to a higher HbA1c level for the same MPG. In type 1 diabetes, the impact of confounding and
effect modiﬁcation of a low versus high SD at an MPG level of 160 mg/dL on the HbA1c level is
7.02 vs. 7.43 and 6.96 vs. 7.41. All GV measures showed the same tendency.
CONCLUSIONS—In only type 1 diabetic patients, GV shows a signiﬁcant interaction with
MPG in the association with HbA1c. This effect is more pronounced at higher HbA1c levels.
However, the impact of GV on the HbA1c level in type 1 diabetes is modest, particularly when
HbA1c is close to the treatment target of 7%.
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S
incethe DiabetesControland Com-
plications Trial (DCCT) and the
UK Prospective Diabetes Study
(UKPDS) (1,2) established the relation-
shipbetweenHbA1candthedevelopment
of long-term diabetes complications,
HbA1c has become the key monitoring
tool in diabetes management.
During the lifetime of the erythrocyte,
hemoglobin(Hb)isgraduallyglycated.The
proportion of the glycated sites, HbA1c,
within the erythrocyte increases through-
out its life span and reﬂect the exposure to
mean blood glucose (MBG) levels during
the preceding 2–3m o n t h s( 3 ) .T h i sn o n -
enzymaticposttranslationalmodiﬁcationis
relatively slow. In vivo and in vitro studies
have shown that HbA1c levels are directly
proportional to the time-averaged con-
centration of glucose during the erythro-
cyte’s life span (3–6). Given the kinetics
of glycation, brief periods of hyperglyce-
mia should not have a major impact on
HbA1c levels (7–9).
However, increased glycated protein
levels are documented in some nondia-
betic pathological states. So, hyperglyce-
mia is not the complete answer to the
etiology of increased early glycated prod-
uctsinnondiabeticconditions.Acommon
denominator is oxidative stress. It has
been hypothesized that oxidative stress
either via increasing reactive oxygen spe-
cies or by depleting the antioxidants may
modulate the genesis of early glycated
proteins in vivo (10,11). Hyperglycemia
stimulates oxidative stress (12) and glu-
cosevariability;inparticular,postprandial
glucose excursions have been regarded
as potentially deleterious as a result of,
among other factors, their association
with the increase of oxidative stress (13).
Therefore, glucose variability (GV) could
inﬂuence the glycation of HbA1c.
Previous studies have examined
whether the relationship between mean
plasmaglucose(MPG)levelsandHbA1cis
inﬂuenced by glucose variability and
found no or minimal inﬂuence (10,14,15).
However, these studies used limited self-
monitoring of blood glucose (SMBG) data
to assess mean glucose levels and variabil-
ity inrelatively small numbersof measure-
ments.Thesemethodscouldunderestimate
glycemic excursions. Continuous glucose
monitoring (CGM) provides a more com-
plete view of glycemic excursions, includ-
ing the duration and frequency of the
excursions, and allows calculation of
features of GV. Our aim was to examine
the inﬂuence of GV on the MPG-HbA1c
relationship in the A1C-Derived Average
Glucose (ADAG) study.
RESEARCH DESIGN AND
METHODS—The ADAG study was
conducted at 10 centers in the U.S.,
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Pathophysiology/Complications
ORIGINAL ARTICLEEurope,andAfricafrom2006to2008to
deﬁne the relationship between HbA1c
and average glucose levels. Because a
full description of this observational
study has been published (14), we de-
scribe it here only brieﬂy. A total of
268 individuals with type 1 diabetes
and159individualswithtype2diabetes
(age 18–70 years) completed the study.
Participants were selected based on sta-
bleglycemiccontrolasevidencedbytwo
HbA1c values within one percentage
pointofeachotherinthe6monthsprior
to recruitment. Individuals with a wide
range of HbA1c levels were included.
Participants with conditions leading
to major changes in glycemia (infectious
disease, steroid therapy, and pregnancy)
orconditionsthatmightinterferewiththe
measurement of HbA1c or the relation-
ship between HbA1c and MPG (hemoglo-
binopathies [16], anemia, increased
erythrocyte turnover, blood loss and/or
transfusions, or chronic renal or liver dis-
ease) were excluded (14). The study was
approved by the human studies commit-
tees at the participating institutions, and
informed consent was obtained from all
participants.
Measurements of glycemia
During the study period, CGM (Med-
tronic Minimed, Northridge, CA) was
performed at home four times with 4-week
intervals during the 16-week study pe-
riod.Monitoringperiodlastedatleast48h,
during which time glucose levels were
assessed every 5 min. CGM data were
accepted for analysis if there were no gaps
longer than 120 min and if the mean
absolute difference with the Hemocue
calibration results was ,18%, as recom-
mended by the manufacturer. For calibra-
tion purposes, participants performed
SMBGwiththeHemocuemeter(Hemocue
Glucose 201 plus; Hemocue, Ängelholm,
Sweden) during the days of CGM.
For adequate calculation of MPG,
subjects additionally performed a seven-
point SMBG (OneTouch Ultra; Lifescan,
Milipitas, CA) for at least 3 days per week
during the weeks when CGM was not
performed. All blood glucose values
stated are plasma equivalents.
HbA1c samples were analyzed with
fourhighlyintercorrelatedDCCT-aligned
assays: a high-performance liquid chroma-
tography assay, two immunoassays, and
an afﬁnity assay (all approved by the Na-
tional Glycohemoglobin Study Program).
The mean HbA1c value at the end of the
12 week study period was used (14).
Calculating glucose variability
Three indicesofintraday glucose variabil-
ity werecalculatedbasedonCGM:theSD
ofmeanglucoseconcentrations,themean
amplitudeofglycemicexcursions(MAGE),
and the continuous overlapping net
glycemic action (CONGA). High SD,
MAGE, and CONGA values indicate high
intraday glucose variability. MAGE is the
mean of the differences between consec-
utive peaks and nadirs, only including
changes of .1 SD of glycemic values and
thus capturing only major ﬂuctuations
(17). For the calculation of CONGAn,
t h ed i f f e r e n c eo ft h ec u r r e n tv a l u ec o m -
pared with the value n hours previously
was calculated for each observation after
the ﬁrst n hours. The CONGAn is the SD
of these differences (18). In the analyses,
w eu s e dC O N G Aa t4h( C O N G A 4). Cal-
culationsbased onCGM data werecalcu-
lated after exclusion of the initial 2 h of
monitoring, which is considered to be an
unstable calibration period.
Statistical analysis
First, we explored the correlations be-
tween MPG and HbA1c and measures of
glycemic variability as SD, MAGE, and/or
CONGA4forthetotaldiabeticpopulation
and the two diabetes types. Multiple lin-
ear regression was used to investigate
confounding and effect-modifying inﬂu-
ence of clinical parameters (glycemic var-
iability) on the relation between the
determinant (MPG) and outcome (HbA1c)
of interest. We then assessed which of the
variability measures (SD, MAGE, or
CONGA4) had the strongest impact on
the MPG-HbA1c relationship by con-
founding or effect modiﬁcation.
Effect modiﬁcation was concluded
when the slope of the interaction term of
glycemic variability and determinant was
signiﬁcant.Ifnoeffectmodiﬁcationmight
be concluded, a parameter DBw a sc o m -
puted as the relative difference of the
slope of the determinant in the model
without and with the clinical parameter.
Confounding was concluded when the
absolute value of DB exceeded the gener-
ally accepted threshold of 10%.
Multivariate confounding was inves-
tigated with a variant of stepwise regres-
sion, in which the stepping criterion was
not a P value but the DBa sl o n ga si te x -
ceeded the threshold. For signiﬁcance, a
threshold of a = 0.05 was used.
Analyses were done for the total pop-
ulationandstratiﬁedforthetypeofdiabetes.
Finally, we illustrated the magnitude of
the effect caused by the variability indices,
by confounding or effect modiﬁcation, on
the MPG-HbA1c relationship.
RESULTS—Of the 507 patients en-
rolled, 427 completed the study and had
adequate glucose monitoring and HbA1c
samplesforinclusionintheanalyses.Two
hundred and sixty-eight participants had
type 1 diabetes, and 159 had type 2 diabe-
tes. The CGM and the SMBG data during
the 3-month period included approxi-
mately 2,400 and 300 measurements per
subject, respectively. The relationship be-
tween the HbA1c level at the end of the
3-month study period and MPG calcu-
lated over the preceding 3 months was
expressed as the simple linear regressions.
The formula for the total diabetic popula-
tion was as follows: HbA1c (%) = 0.028 3
MPG (mg/dL) + 2.66 (R
2 = 0.80). The for-
mula for type 1 diabetes was as follows:
HbA1c (%) = 0.028 3 MPG (mg/dL) +
2.77 (R
2 = 0.77). The formula for type 2
diabetes was as follows: HbA1c (%) =
0.0283MPG(mg/dL)+2.62(R
2=0.82).
The clinical and glycemic character-
istics are shown in Table 1. Mean HbA1c
(SD)fortype1 diabeticpatientswas7.3%
(1.1) and for type 2 diabetic patients was
6.8% (1.1).
All GV measures had signiﬁcant in-
ﬂuence on the MPG-HbA1c relationship
for the total population. The variability
index SD showed the strongest inﬂuence
on the MPG-HbA1c relationship. None of
theGVmeasuresshowedconfoundingfor
all diabetic patients pooled or for the type
1 or type 2 diabetic patients separately
(Table 2).
In the type 1 diabetic patients, the
effect modiﬁcation of SD and CONGA4
was signiﬁcant (P , 0.01 and P = 0.02),
and for the MAGE it was just not signiﬁ-
cant(P=0.06)(Table2).TheMPG/HbA1c
linear regression formula with confound-
ing for type 2 diabetes was as follows:
HbA1c (%) = 2.64 + 2.63 3 MPG/100 +
0.58 3 SD/100. The MPG-HbA1c linear
regression formula with effect modiﬁca-
tion for type 1 diabetes was as follows:
HbA1c (%) = 3.91 + 1.79 3 MPG/100 2
1.37 3 SD/100 + 1.25 3 MPG/100 3
SD/100.Theimpactofeffectmodiﬁcation
o fl o wG V( S D=3 0m g / d L )v e r s u sh i g h
GV (SD = 100 mg/dL) for an MPG level of
160 mg/dL in type 1 diabetes on the
HbA1c level was 6.96 vs. 7.41%, respec-
tively, as shown in Table 3. At an MPG
level of 220 mg/dL (HbA1c following the
regressionformulaof 8.89%),adecline in
the SD parameter from 100 to 30 mg/dL
reduced HbA1c from 9.23 to 8.26%.
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Glucose variability, plasma glucose, and HbA1cFor all patients pooled, there was no
effect modiﬁcation of the respective GV
measures on the MPG-HbA1c relation-
ship. For type 2 diabetic patients, the im-
pact of effect modiﬁcation from the
respective GV measures was far from sig-
niﬁcant(Table2).Thenumberofpatients
with a predeﬁn e dS Di ss h o w ni nT a b l e1
for all patients pooled and for the type 1
and type 2 diabetic patients separately.
CONCLUSIONS—Thisstudydemon-
strated a signiﬁcant effect of GV, as
reﬂected by SD, on the MPG-HbA1c rela-
tionship. High GV (SD) is associated with
higher HbA1c levels for a given MPG, and
thiseffectwasmorepronouncedathigher
HbA1c and MPG values. However, the
magnitude of this effect of GV was small
and only demonstrable in type 1 diabetic
patients. Possibly, the type 2 diabetic pa-
tient group was too small (n = 159) and
thevariabilityinthisgrouptoolowtoﬁnd
this interaction.
T h eA D A Gs t u d ys h o w e dat i g h t
correlation between HbA1c and MPG, al-
lowing the translation of HbA1c into esti-
mated average glucose (14,19). It has
been suggested that GV could affect the
MPG-HbA1c relationship, but this has not
previously been demonstrated (20–22).
To our knowledge, the current study is
the largest study reporting an inﬂuence
of GV—as expressed by SD, MAGE, and
CONGA4 calculated from CGM—on the
MPG-HbA1c relationship. The discrepan-
cies in the MPG-HbA1c relationship are
less likely caused by technical errors be-
cause this study included accurate and
centralized measurements of HbA1c val-
ues and intensively measured plasma glu-
cose concentrations (;2,700 values) in a
large and diverse population. Also, indi-
viduals with conditions or treatment that
might result in major changes in glycemia
or interference with the HbA1c assay, or
the MPG-HbA1c relationship, were ex-
cluded. These precautions allowed us to
search for factors other than MPG that
may contribute to HbA1c.
In general, GV is higher in patients
with poor glycemic control and in type 1
diabetic patients compared with type 2
diabetic patients, which can be attributed
to insulin therapy and higher insulin
sensitivity. High GV may affect glycation
becauseofperiodicexposureoftheeryth-
rocytetohighglucoselevelsandtherefore
to faster irreversible glycation.
Other factors like hyperglycemia-
induced oxidative stress may affect the
glycation process. In recent literature, it
has been speculated that oxygen free rad-
icals per se or with an associated decrease
in antioxidants may modulate the forma-
tion of early glycated protein (10,11).
Brownlee (12) demonstrated that hy-
perglycemia stimulates oxidative stress.
High GV and especially postprandial glu-
cose excursions were also previously
Table 1—Baseline clinical and glycemic characteristics
All Type 1 diabetes Type 2 diabetes
n 427 268 159
Age (years) 47.6 6 13.6 44.1 6 12.9 56.6 6 9.4
Sex (% female) 54 52 51
Ethnicity (% non-Hispanic whites) 83 93 73
Current smokers 11 12 9
Insulin treatment 76 100 38
Glycemic measures
HbA1c (%) 6.8 6 1.3 7.3 6 1.1 6.8 6 1.1
MPG (mg/dL) 149.4 6 39.6 162 6 36 149.4 6 36
Measures of GV
CGM SD (mg/dL) 48.6 6 25.2 64.8 6 16.2 39.6 6 16.2
MAGE (mg/dL) 86.4 6 43.2 115.2 6 32.4 68.4 6 27
CONGA4 (mg/dL) 66.6 6 28.8 88.2 6 23.4 52.2 6 21.6
SD (mg/dL)
#30 61 (14.3) 9 (3.4) 52 (32.7)
,30–60 173 (40.5) 84 (31.3) 89 (56)
,60–90 173 (40.5) 155 (57.8) 18 (11.3)
.90 20 (4.7) 20 (7.5) 0 (0)
Data are means 6 SD, %, or n (%).
Table 2—The P values of the inﬂuence of the respective GV measures themselves, as well as effect modiﬁcation and the D of
confounding, calculated from the respective slopes (B and B9) from the regression equations, on the HbA1c-MPG relationship for all
patients pooled and for type 1 and type 2 diabetic patients separately
Inﬂuence of the GV
measure (P)
S l o p eo fM P G( B )i nt h e
main regression formula
Slope of MPG (B9) in the regression
formula with the GV measure
DConfounding
(%)*
Effect
modiﬁcation (P)
SD
All ,0.01 2.818 2.624 6.9 0.06
Type 1 diabetic 0.01 2.781 2.631 5.4 ,0.01
Type 2 diabetic 0.06 2.782 2.637 5.2 0.74
MAGE
All ,0.01 2.818 2.700 4.2 0.37
Type 2 diabetic 0.19 2.781 2.721 2.2 0.06
Type 2 diabetic 0.19 2.782 2.698 3.0 0.19
CONGA4
All ,0.01 2.818 2.667 5.4 0.15
Type 1 diabetic 0.06 2.781 2.687 3.4 0.02
Type 2 diabetic 0.07 2.782 2.661 4.3 0.46
*DConfounding in % = 100 3 absolute (B9 – B)/B.
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Kuenen and Associatesassociated with oxidative stress in type 2
diabetes (13). The activation of oxidative
stress, estimated from urinary excretion
rates of isoprostanes, was highly corre-
l a t e dw i t hM A G Ec a l c u l a t e df r o mC G M
(13).However,Wentholt et al. (23) could
not replicate these results in type 1 diabe-
tes. Recently, Ceriello et al. (15) demon-
strated that high intraday GV was more
damaging to endothelial function than
stable hyperglycemia and that oxidative
stress plays a key role. Whether oxidative
stress inﬂuences glycation needs to be
determined.
On the other hand, it has been dem-
onstrated that erythrocyte survival is
shorter at chronic high glucose concen-
trations levels, which might falsely lower
HbA1c levels. Peterson et al. (24) showed
that the life span of 51Cr-labeled eryth-
rocytes increased in all seven subjects
when their poorly controlled diabetes
was adequately treated. Virtue et al. (25)
concluded that there is a hyperglycemia-
related decrease in erythrocyte survival as
measured by carbon monoxide in the
expired air, which results in an exponen-
tial underestimation of the severity of
hyperglycemia at higher HbA1c levels.
Similarly, hyperglycemia-related osmotic
stress may inﬂuence erythrocyte perme-
ability and could cause damage to the
erythrocyte and shorten its life span.
These ﬁndings could lead to underesti-
mation of HbA1c at higher MPG levels,
concealing a glycemic control worse
than indicated by HbA1c measurements.
However, we found that type 1 diabetic
patients with high GV display higher
HbA1c levels than suspected based on
MPG. This effect was more pronounced
at higher HbA1c levels, indicating that fo-
cuson reducing GV,especially in patients
with poor glycemic control, could help
reduce HbA1c levels.
LimitationsofourstudyarethatCGM
has a limited range of reliable measure-
ments between 2.2 mmol/L and 22.2
mmol/L. Therefore, theoretically, CGM
performance could be less precise in
patients with high glycemic variability.
Furthermore, CGM has a lag time in
glucose values compared with the venous
measured values (the physiological gap),
and this can result in underestimation of
the inﬂuence of GV on the glycation of
HbA1c, and no measures of erythrocyte
survival, oxidative stress, or clinical fol-
low-up are available in this population.
In conclusion, at higher levels of GV
therelationship between HbA1c andMPG
in patients with type 1 diabetes is altered,
leading to a higher HbA1c level fora given
MPG.However,theimpact(neartheHbA1c
treatment target of 7%) is only modest.
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